Frontiers in medicine · 2026
Exploring the efficacy of repeated low-level red-light therapy in retarding childhood myopia progression: updated systematic review and meta-analysis.
СтатьяСистематический обзорНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Liu Chen, Zhou Yating, Zhan Zongyue, Li Xiaofeng
Аннотация
BACKGROUND: Due to the increasing prevalence of childhood myopia, low-level red-light therapy has surfaced as a non-pharmacological method to mitigate its advancement. This systematic review and meta-analysis evaluates the efficacy of repeated low-level red-light (RLRL) in pediatric populations, providing evidence-based support for its therapeutic usage.
METHODS: A search was performed in PubMed, Web of Science, Cochrane Library, Embase, and prominent Chinese databases, including CNKI, VIP, and Wanfang, from their inception until May 13, 2025. This meta-analysis includes randomized controlled trials (RCTs) that matched the inclusion criteria and was analyzed using Stata software, version 18.0.
RESULTS: This meta-analysis included 1,053 participants: 515 in the RLRL and 538 in the control groups. The SMD for SER reduction was 0.84 (95% CI: 0.50, 1.19), SMD for AL reduction was -1.01, (95% CI: -1.60, -0.41), and SMD for SFChT rise was 0.81 (95% CI: 0.65-0.98). There is no major publishing bias.
CONCLUSION: The meta-analysis found that children with myopia who got RLRL therapy in addition to normal treatment had significantly slower disease progression than the control group.
SYSTEMATIC REVIEW REGISTRATION: https://www.crd.york.ac.uk/PROSPERO/view/CRD420251034037, PROSPERO 2025 CRD420251034037.
METHODS: A search was performed in PubMed, Web of Science, Cochrane Library, Embase, and prominent Chinese databases, including CNKI, VIP, and Wanfang, from their inception until May 13, 2025. This meta-analysis includes randomized controlled trials (RCTs) that matched the inclusion criteria and was analyzed using Stata software, version 18.0.
RESULTS: This meta-analysis included 1,053 participants: 515 in the RLRL and 538 in the control groups. The SMD for SER reduction was 0.84 (95% CI: 0.50, 1.19), SMD for AL reduction was -1.01, (95% CI: -1.60, -0.41), and SMD for SFChT rise was 0.81 (95% CI: 0.65-0.98). There is no major publishing bias.
CONCLUSION: The meta-analysis found that children with myopia who got RLRL therapy in addition to normal treatment had significantly slower disease progression than the control group.
SYSTEMATIC REVIEW REGISTRATION: https://www.crd.york.ac.uk/PROSPERO/view/CRD420251034037, PROSPERO 2025 CRD420251034037.